Skip to Main Content

Author Details

Melissa L Abel
National Cancer Institute, National Institutes of Health
2013
15
11
PMIDPaper TitleJournal TitlePublished Year
37227187Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.Clin Cancer Res2023
36980699The Potential Revolution of Cancer Treatment with CRISPR Technology.Cancers (Basel)2023
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
34913366Inequity in Cardio-Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes.J Am Heart Assoc2021
33558159The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.Clin Genitourin Cancer2021
29475973Microbiota promote secretory cell determination in the intestinal epithelium by modulating host Notch signaling.Development2018
30018082Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.Sci Signal2018
29872570Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.Oncoimmunology2018
30333627Functional genomic landscape of acute myeloid leukaemia.Nature2018
28219391Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.World J Surg Oncol2017
26677978Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.Cancer Res2016
26475333The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.Clin Cancer Res2016
24403076Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.J Biol Chem2014
24895378Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics.Mol Cell Proteomics2014
24081659The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.Blood2013
  • 1 - 15 of 15

Recommended Authors

Memorial Sloan Kettering Cancer Center
Career Start Year 2016
Number of shared co-authors 0
Baptist Cancer Center
Career Start Year 2013
Number of shared co-authors 0
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
The University of Texas Southwestern Medical Center
Career Start Year 2009
Number of shared co-authors 18
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 0
Sandra and Edward Meyer Cancer Center
Career Start Year 2007
Number of shared co-authors 1
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 1
Duke University
Career Start Year 2005
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 2
Weill Cornell Medical College
Career Start Year 2004
Number of shared co-authors 1
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 0
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 0
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 9
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 2
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 2
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 0
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 0
University of California San Diego Moores Cancer Center
Career Start Year 1992
Number of shared co-authors 0
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 0
University of Leicester
Career Start Year 1990
Number of shared co-authors 0
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 0
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 3
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 3
Mayo Clinic
Career Start Year 1982
Number of shared co-authors 0
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 2
National Cancer Institute, National Institutes of Health
Career Start Year 1974
Number of shared co-authors 3

Collaborators

Oregon Health & Science University School of Medicine
Co-authored papers 8
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 6
Oregon Health & Science University
Co-authored papers 5
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 4
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Oregon Health & Science University, University of California Berkeley
Co-authored papers 4
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Oregon Health and Science University
Co-authored papers 3
Oregon Health and Science University
Co-authored papers 2
Astex Pharmaceuticals
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Oregon Health & Science University, Knight Cancer Institute
Co-authored papers 2
Oregon Health & Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Emory School of Medicine
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Oregon Health & Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health Sciences University
Co-authored papers 2
University of Miami, Sylvester Comprehensive Cancer Center
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2